8.00
+0.32(+4.17%)
Currency In USD
| Previous Close | 7.68 |
| Open | 7.63 |
| Day High | 8.6 |
| Day Low | 7.6 |
| 52-Week High | 26.6 |
| 52-Week Low | 5.12 |
| Volume | 80,663 |
| Average Volume | 55,440 |
| Market Cap | 25.43M |
| PE | 0.2 |
| EPS | 39.4 |
| Moving Average 50 Days | 6.78 |
| Moving Average 200 Days | 8.76 |
| Change | 0.32 |
If you invested $1000 in Passage Bio, Inc. (PASG) since IPO date, it would be worth $18.02 as of September 28, 2025 at a share price of $8. Whereas If you bought $1000 worth of Passage Bio, Inc. (PASG) shares 3 years ago, it would be worth $305.34 as of September 28, 2025 at a share price of $8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 28, 2025 11:00 AM GMT
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participat
Passage Bio Announces 1-for-20 Reverse Stock Split
GlobeNewswire Inc.
Jul 10, 2025 11:00 AM GMT
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announce
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
GlobeNewswire Inc.
Jun 23, 2025 11:00 AM GMT
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days